Citation Impact
Citing Papers
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy
2008
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma
2005
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
2005 Standout
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
2003 Standout
Nasopharyngeal carcinoma
2005 Standout
The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma
2015
Cancer to bone: a fatal attraction
2011 Standout
Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study
2002
A robust cell culture system supporting the complete life cycle of hepatitis B virus
2017 StandoutNobel
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy
2001
Hallmarks of aging: An expanding universe
2023 Standout
Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update*
2003
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Triple-negative breast cancer: treatment challenges and solutions
2016
Hepatitis B virus infection
2009 Standout
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
2004 Standout
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Hepatitis B reactivation after chemotherapy: two decades of clinical research
2008
Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth
2006
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
2016
Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease
2015
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
2006 Standout
Chronic hepatitis B
2007 Standout
Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases
2003
Raf kinases: Oncogenesis and drug discovery
2006
Chronic hepatitis B: Update 2009 #
2009 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma
1994
Zibotentan for the treatment of castrate-resistant prostate cancer
2010
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
2001
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Genomic Analysis Reveals a Potential Role for Cell Cycle Perturbation in HCV-Mediated Apoptosis of Cultured Hepatocytes
2009 StandoutNobel
Prevention of Hepatitis B reactivation in the setting of immunosuppression
2016
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment
2016
The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B
2003
Liposomes as nanomedical devices
2015 Standout
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
2016
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
2015
G protein-coupled receptors: novel targets for drug discovery in cancer
2010
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
2003 Standout
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Hepatocellular carcinoma
2022 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
2003 Standout
Prevention and Treatment of Cancer-Related Infections
2012
Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies
2017
Endothelin B Receptor, a New Target in Cancer Immune Therapy
2009
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Ipilimumab Administration in Patients With Advanced Melanoma and Hepatitis B and C
2013
The Challenge of Viral Reservoirs in HIV-1 Infection
2002
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy
2014
Breast Cancer Treatment
2019 Standout
Ionizable lipid nanoparticles for in utero mRNA delivery
2021 StandoutNobel
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues
2006
Bone Metastases: Molecular Mechanisms and Novel Therapeutic Interventions
2010
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Emerging Targets in Photopharmacology
2016 StandoutNobel
Analysis of nanoparticle delivery to tumours
2016 Standout
Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies
1999
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms
2021
Works of Joyce Steinberg being referenced
Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid
1992
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer
2008
Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy
1999
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors
2000
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer
2018
Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors
2004
Targeting the unmet medical need: the Abbott Laboratories oncology approach.
2005
Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC)
2007
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
2018
Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
2015
A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer.
2014
Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
2015
Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role
2000
Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir.
1998
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).
2015